ROLE OF ANTI-INFLAMMATORY AND IMMUNOMODULATORY AGENTS IN RHEUMATOID ARTHRITIS.

BY
Amany El-Shahawy Abdel-Maged\textsuperscript{a}, Amany M. Gad\textsuperscript{b}, Amal Kamal Abdel-Aziz\textsuperscript{c}, Mohammad M. Aboulwafa\textsuperscript{d}, Samar S. Azab\textsuperscript{c}

FROM
\textsuperscript{a}: National Organization for Research and Control of Biologicals (NORCB), Cairo, Egypt
\textsuperscript{b}: Department of Pharmacology, National Organization for Drug Control and Research (NODCAR), Cairo, Egypt
\textsuperscript{c}: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
\textsuperscript{d}: Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

* Correspondence: All correspondence should be addressed to:
Samar S. Azab
Pharmacology and Toxicology Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt

Abstract:
This review is an attempt to illustrate the co-relation between inflammatory cytokines (such as IL-6, TNF alpha and IL-1), angiogenic markers (such as VEGF and TGFβ), apoptotic markers (such as Bax and caspase-3) and their relation to bone protection (OPG and RANKL). It also shows the role of each in rheumatoid arthritis (RA) progression. As the pathogenesis of RA depends on massive inflammation and neovascularization.
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune inflammatory disease associated with irreversible joint destruction which leads to permanent motor disability and compromised quality of life. It carries essential or real burden on the patient or individual and the society. The patient burden comes from joints destruction and deficits that lead to decline in daily physical function, comorbidities risks and finally quality of life. While, the economic burden on the society results from medical costs and decreased work capacity due to disability (McInnes and Schett, 2011).

The incidence of rheumatoid arthritis is 0.5 – 1 %. This incidence may be differ from rural and urban areas. It also may decrease from north to south. According to the World Health Organization (WHO), RA predominantly strikes during the most productive years of adulthood and within 10 years of its onset, more than half of RA patients in developed countries lose their full-time jobs (Briggs et al., 2016).

The main cause of RA is unknown till now, although a lot of factors could be involved in its occurrence or trigger its mechanism of development such as susceptibility genes, environmental factors (smoking, low socioeconomic status and low educational attainment) in addition to alcohol consumption. Moreover, microbiomes (microbial populations in oral, salivary and GIT sites) are associated with CRP level and may be involved in triggering of RA (Barton and Worthington, 2009; Carlens et al., 2010).

Rheumatoid arthritis affects the joints mainly the synovium of joint. Cartilage destruction and bone erosion develop during late stages of RA after occurrence of synovitis, synovial hyperplasia, pannus formation, stiffness and joint swelling (Kotake et al., 1996; Maeno et al., 2004; McInnes and Schett, 2011; Briggs et al., 2016). In conjunction with its articular manifestations, RA patients usually suffer from coexisting autoimmune hepatitis and splenomegaly. RA also affects other organs as lung, skeletal muscles and heart (Marra, 2006; Turesson and Matteson, 2006).

Although the precise etiology of RA remains obscure, heightened immune response is thought to play a vital role in provoking joint inflammation and bone erosion (Garnero et al., 2010; Kremer et al., 2011) (Fig. 1).
In this context, infiltrating synovial tissue/joints with immune cells and synoviocytes produce proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukins (ILs) including IL-1β, IL-6, IL-17 and IL-18 that regulate synovial cell proliferation (Firestein, 2003; Sebba, 2008) (Fig. 2).
However, several pro-inflammatory cytokines are involved in RA development, IL-6 is the key inflammatory mediator in RA (2012; Tanaka et al., 2012). IL-6 is a pro-inflammatory cytokine with a pleiotropic activity. IL-6 is produced from different/ various immune cells like/such as synovocytes (synovial fibroblastic cells) in response to synovocytes stimulation/activation by different/ various cytokines like TNF, IL-17 and IL-1 or (others) in response to infection, trauma and immunological challenges (Kotake et al., 1996; Palmqvist et al., 2002; Hashizume and Mihara, 2011). IL-6 has multiple/ many functions depending on its signaling pathway where it binds with two types of receptors: membrane bound IL-6 receptor (mIL-6R) and soluble IL-6 receptor (sIL-6R) which lacks/ loses its intracytoplasmic portion of mIL-6R (Kishimoto et al., 1992; Narazaki et al., 1993; Rose-John and Neurath, 2004; Mihara et al., 2005).

After IL-6 binding with its receptors, it forms a complex which will be associated/ linked with a signal transducer glycoprotein 130 (gp130) that is expressed on different/various immune cells unlike/ in contrast to mIL-6R which is expressed only on limited/certain immune cells such as/like hepatocytes and certain types of leukocytes (Kishimoto, 2006). After that signals transduction occurs/happens via several mediators of Janus-activated kinase-signal transducer and activator of transcription (JAK/STAT) pathway which finally leads to gene transcription (Heinrich et al., 1998). This signal transduction pathway is called trans-signaling pathway. IL-6 has two different features/characters that based/depend on its signaling pathway including; (A) pro-inflammatory features/characters that are correlated to trans-signaling mechanism and (B) its anti-inflammatory features/characters that are secondary to classic signaling mechanism (Calabrese and Rose-John, 2014). IL-6 contributes to/involves in RA development through various/different actions/mechanisms such as differentiation of activated B-cells into plasma cells (antibody producing cells), and naïve (lymphocyte T-helper 1 cell) Th-1 (synergically with transforming growth factor beta (TGFβ)) into (lymphocyte T-helper 17 cell) Th-17 which involved in RA progression and production of other inflammatory cytokines (Iwanami et al., 2008). Furthermore, IL-6 is involved in joint/cartilage destruction via/through osteoclastogenesis that is responsible for focal bone erosion, proliferation of synovocytes and differentiation of osteoclast through/via receptor activator of NF-Kappa B ligand (RANKL) expression. Interleukin-6 (IL-6) is also participated with IL-1 in production of matrix metalloproteinases (MMPs) from synovial cells that involved in cartilage destruction and bone erosion (FUJIKAWA et al., 1996; Mohamed, 2008; Suzuki et al., 2010).

Beside alongside its effect/action on osteoclast, IL-6 enhances/improves angiogenesis (formation of new blood vessels from existing ones) and vascular permeability of synovial tissue through/via inducing/inducing production of vascular endothelial growth factor (VEGF) from synovial fibroblast (Nakahara et al., 2003). VEGF is also produced secondary to/in response to simulation/ activation by TGFβ (Frater-Schroder et al., 1987). Synovial angiogenesis contributes to/ participates in maintenance of inflammation and progression of RA (Maruotti et al., 2006). VEGF that is produced from
different/various inflammatory cells such as/ like macrophages, fibroblasts, vascular smooth muscles cells and synovial lining cells (Ballara et al., 2001; De Bandt et al., 2003) is the most important and powerful angiogenic factor/marker in RA development/progression that contributes/correlates to or participates in pannus formation (Nakahara et al., 2003; Hashizume et al., 2009).

Similar to Il-6, VEGF produces/appears at early stage and it is maintained throughout RA disease course (Ballara et al., 2001). Serum and synovial levels of IL-6 and VEGF are correlated with/ linked to disease activity (Hirano et al., 1988; Houssiau et al., 1988; Guerne et al., 1989; Madhok et al., 1993). Serum concentrations of VEGF also correlate with serum levels of C-reactive protein (CRP) that is considered as an inflammatory biomarker/factor in RA and produced from hepatocytes secondary to/ in response to stimulation/activation by IL-6, so it is produced at the early stage of the disease and its concentrations correlate with severity of the RA (Paleolog and Miotla, 1998). Moreover, VEGF contributes/relates to the proliferation of synovial tissues. Neovascularization/angiogenesis permits/ allows infiltration of more and more inflammatory cells that worse the disease state (Maruotti et al., 2006).

On the other hand, Apoptosis has a role in most auto-immune disease. Apoptosis is a programmed cell death type I (PCD). It is involved in both physiological and pathological process. It participates in normal cell turnover, proper development and functioning of immune system. Inadequate or Inappropriate apoptosis is correlated to several diseases/pathologies such as neurodegenerative disease and autoimmune disorders. Apoptosis occurs normally during growth/development and aging. It also has homeostatic role/mechanism to maintain/preserve cell populations in tissues. Sometimes It occurs as a defense mechanism in secondary to/ response to immune response/ immunological reactions or cellular destruction caused/induced by disease or harmful agents (Norbury and Hickson, 2001).

Apoptosis composed/consists of two pathways, one of both is intrinsic pathway and other is extrinsic pathway (Fig. 3).

**Fig.3. Pathways of apoptosis (Favaloro et al., 2012).**
The extrinsic pathway of apoptosis initiates or starts apoptosis via transmembrane receptor-mediated interactions (Fig. 3). These include or involve death receptors which are considered members of the tumor necrosis factor (TNF) receptor gene superfamily (Locksley et al., 2001). These death receptors have a cytoplasmic domain of about 80 amino acids called the “death domain” (Ashkenazi and Dixit, 1998). This death domain plays a vital or critical role in transmitting the death signal from the cell surface into the cell (intracellular signaling pathways). To date, the best-characterized ligands and corresponding death receptors include FasL/FasR, TNF-α/TNFR1 (Elmore, 2007; Nangia-Makker et al., 2007). The sequence of events that define this pathway are best characterized with those models. There is grouping of receptors that bind with ligand. Upon ligand binding, cytoplasmic adapter proteins (ex, FADD adaptor proteins) which exhibit corresponding death domains that bind with the receptors are recruited. The binding of Fas ligand to Fas receptor results in the binding of the adapter protein FADD and the binding of TNF ligand to TNF receptor results in the binding of the adapter protein TRADD with recruitment of FADD and RIP (Wajant, 2002). After that FADD binds with procaspase-8 through or via dimerization of the death effector domain (DED). Finally, a death-inducing signaling complex (DISC) is formed and procaspase-8 is activated. Once caspase-8 is activated, the execution phase of apoptosis is triggered. Death receptor mediated apoptosis can be inhibited by a protein called c-FLIP which will bind to FADD and caspase-8, rendering them ineffective (Kischkel et al., 1995; Scaffidi et al., 1999).

On the other hand, the intrinsic pathway mainly depends on cytochrome c which released from intermembrane space of mitochondria into cytoplasm of the cell after Bax and Bak aggregation on the mitochondrial membrane and forming BH123 channel that allows/permits release of cytochrome c (Saelens et al., 2004). In this pathway cytochrome c is triggering apoptosis via/through activation of caspases (caspase cascade reaction). Caspases are widely expressed in form of an inactive proenzyme in majority of cells. After that it can activate other procaspases which lead to amplification of the apoptotic signaling pathway and finally leading to rapid cell death. Aggregation of Bax/Bak that cause changing in permeability of mitochondrial membrane. This process can be controlled and regulated by the Bcl-2 family of proteins (Cory and Adams, 2002). The Bcl-2 family can be either pro-apoptotic such as Bax or anti-apoptotic such as Bcl-2, Bcl-X, and Bcl-Xs.

In RA, there is a relationship between angiogenic cytokines, bone erosion markers and apoptosis process. So, apoptosis (apoptotic process) participates in RA pathophysiology. TGFβ increases apoptosis in the synovium (Firestein et al., 1995). Furthermore, RANKL induces apoptosis of osteoblasts (Goldring, 2003). Heightened and lessened activity of apoptotic machinery have been both reported (Catrina et al., 2002). During early stage of RA, apoptosis is inhibited resulting in rapid cell proliferation along with increasing cellular influx from blood into the synovium (Firestein et al., 1995). This increases cytokines production and inflammation resulting in hyperplasia, the prominent feature of RA. In contrast, later stage of RA is characterized by intensified apoptosis secondary to increased expression of p53, a critical regulator of synovial fibroblast like cell proliferation, apoptosis and invasiveness (Tak et al., 2000a; Tak et al., 2000b; Dhaouadi et al., 2007). Remarkably, p53 overexpression was observed in cultured fibroblast like synovocytes derived from RA patients. Western blot analysis and immunoprecipitation
studies also confirmed the high levels of p53 protein in RA synovium compared with forms of arthritis. Another study showed that characteristic DNA ladders were found in DNA isolated from whole RA synovial tissues, suggesting that apoptosis occurs in inflamed synovium (Tak et al., 2000a). Apoptosis also correlated with RA severity (Catrina et al., 2002). This is in accordance with Paul et al., (Tak et al., 2000a) who has reported that apoptosis was increased in late stage RA adjuvant induced arthritis model. Furthermore, it has been shown that T-cells in rheumatoid synovial expressed low Bcl-2, high Bax and High Fas, a phenotype that suggests increased susceptibility of T-cells to apoptosis.

While using, apoptosis inducing agents may be useful in early stage of RA to overcome the rapid proliferation of cells and inhibit recruitment of inflammatory cells in RA synovium, the continuous apoptotic effect and/or further apoptosis induction aggravate bone erosion. Accordingly, the use of anti-apoptotic therapeutic agent or apoptosis inducing agent must be linked with the disease stage.

**Conclusion:**

There is a strong correlation between inflammatory, angiogenesis, apoptotic markers and their relation with bone protection/erosion (Fig. 4)

![Fig.4. Sketch diagram showing crosstalk between inflammatory, angiogenesis, apoptotic markers and their relation with bone protection.](image)

**References**


Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. (2005). Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. *Int Immunopharmacol* 5(12): 1731-1740.


Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M (2010). IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. *Cytokine* 51(2): 178-183.


 دور المواد المضادة للالتهاب والمعدلة للمناعة في التهاب المفاصل الروماتيدي

للدكتورة

أمانى الشهابى عبد المجيد1 - أماني محمد جاد2 - أمل كمال عبد العزيز3 - محمد مبروك أبوالوفا4 - سمر سعدي الدين عزب1

1 قسم البيوتكنولوجى، الهيئة القومية للبحوث والرقابة على المستحضرات الحيوية
2 قسم الفارماكولوجى، الهيئة القومية للرقابة والبحوث الدوائية
3 قسم علم الأدوية والسموم، كلية الصيدلة-جامعة عين شمس
4 قسم الميكروبيولوجى والمناعة، كلية الصيدلة-جامعة عين شمس

توضح هذه الدراسة العلاقة بين علامات أو دلالات الإلتهاب (مثل الإنترولكين 6, وعامل نخر الدم، الإنترولكين 1), والعلامات الوعائية (مثل نمو بطانة الأوعية الدموية, وتحويل عامل النمو بيتا), وعلامات موت الخلايا المبرمج (الباكس وكاسباس 3) مع حماية العظام ودور كل منها في طريقة تطور التهاب المفاصل الروماتيدي.

حيث أن الفيزيولوجيا المرضية للالتهاب المفاصل تعتمد على الإلتهاب الشديد وتكون العديد من الأوعية الدموية الجديدة.